Alaunos Therapeutics Regains Nasdaq Listing Compliance
Company Announcements

Alaunos Therapeutics Regains Nasdaq Listing Compliance

Alaunos Therapeutics (TCRT) has released an update.

Alaunos Therapeutics, Inc. has successfully regained compliance with Nasdaq’s minimum $1.00 bid price requirement, ensuring its continued listing on The Nasdaq Capital Market. The company has met all necessary criteria and the issue regarding its listing has been resolved. It will, however, be under a mandatory panel monitor for the next year until February 16, 2025, to ensure ongoing compliance.

For further insights into TCRT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAlaunos Therapeutics Ends Licensing Deal, Reassesses Strategy
TheFlyZIOPHARM Oncology trading halted, news pending
Christine BrownAlaunos Therapeutics Inc (TCRT) Q4 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App